Prevalence of Cervical Cancer in Colonial War Memorial (CWM) Hospital from 2016-2023


Authors : Shayal Sharma; Grace Lasaufmal; Nishal Murthi; Anish Singh; Aruna Devi

Volume/Issue : Volume 10 - 2025, Issue 4 - April

Google Scholar : https://tinyurl.com/4nw3eurw

Scribd : https://tinyurl.com/4rvxnrn4

DOI : https://doi.org/10.38124/ijisrt/25apr455

PlumX Metrics

Semantic Scholar

ResearchGate

IJISRT Repository

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : Cervical cancer is the fourth most common cancer in women globally, with 660,000 new cases reported in 2022 and 350,000 deaths. This study examined cervical cancer prevalence at Fiji's Colonial War Memorial Hospital (CWMH) from June 2016 to December 2023. The overall prevalence was 0.35%, with notable fluctuations: a significant rise from 2016 to 2017, stability until 2019, a COVID-19-related drop in 2020, and a gradual increase by 2023. Of the 352 diagnosed women, 74.15% were Fijian, 21.88% were of Indian ethnicity, and 2.27% were from other groups. Fijian women exhibited higher mortality. The majority (52.55%) of cases occurred in women aged 31-50, peaking at 41-45. Pap smear results showed 87.39% were negative, 11.01% were "Other," and 1.60% indicated epithelial cell abnormalities. The study highlights the persistent need for enhanced cervical cancer screening and prevention in Fiji.

Keywords : Cervical Cancer, Prevalence, Bethesda System, Cervical Intraepithelial Neoplasia.

References :

  1. Akshatha C, Arul P, Shetty S 2017. Prevalence and comparison of cervical cytology abnormalities in postmenopausal and elderly women: A experience from tertiary care hospital. JMS - Journal of Medical Society, 31(1), 23–27.
  2. Alimena S, Pachigolla SL, Feldman S, Yang D, Orio PF, Lee L, King M 2021. Race- And age-related disparities in cervical cancer mortality. JNCCN Journal of the National Comprehensive Cancer Network, 19(7), 789–795.
  3. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, De Sanjosé S 2010. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases, 202(12), 1789–1799.
  4. Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, Prince S 2022. Cervical cancer therapies: Current challenges and future perspectives. In Tumour Virus Research (Vol. 13).
  5. Cancer – Ministry of Health & Medical Services. (n.d.). Retrieved March 2, 2024, from https://www.health.gov.fj/cancer/
  6. Canavan TP, Doshi NR 2024. Cervical cancer. American Family Physician, 61(5), 1369–1376.
  7. CDC 2021. Basic Information About Cervical Cancer | CDC. Division of Cancer Prevention and Control, 21–22.
  8. Cervical Cancer Statistics | Key Facts About Cervical Cancer | American Cancer Society. 2024. https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html
  9. Chatterjee T, Gill S,Rac R 2000. Standization of Cervical/ Vaginal Cytopathology Reporting: The Bethesda System (TBS) For Reporting Cervical/ Vaginal Cytologic Diagnoses. Medical Journal Armed Forces India, 56(1), 45–49.
  10. Dachs GU, Currie MJ, McKenzie F, Jeffreys M, Cox B, Foliaki S, Le Marchand L, Robinson BA 2008. Cancer disparities in indigenous Polynesian populations: Māori, Native Hawaiians, and Pacific people. In The Lancet Oncology (Vol. 9, Issue 5, pp. 473–484).
  11. De Cuba EMV, Snaebjornsson P, Heideman DAM, Van Grieken NCT, Bosch LJW, Fijneman RJ A, Belt E, Bril H, Stockmann HBAC, Hooijberg E, Punt CJA, Koopman M, Nagtegaal ID, Coupé VHM, Carvalho B, Meijer GA 2016. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. International Journal of Cancer, 138(5), 1139–1145.
  12. De Sanjosé, S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N,  Bosch FX 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. In Lancet Infectious Diseases Vol. 7, Issue 7, pp. 453–459.
  13. Duavy LM, Batista FLR, Jorge MSB, Dos Santos JBF 2007. Women’s perceptions of preventive examinations for cervical-uterine cancer: A case study. Ciencia e Saude Coletiva, 12(3), 733–742.
  14. Ezzelarab S, El-Husseiny A, Nasreldin M, Ali R, Nabhan A, Abdel-Razek M, Abdel-Salam M, Abdel-Salam R, Ahmed R, Alloub A, Alqenawy H, Alshabrawy A, Awad N, Ayaad S, El-Sallaly H, El-Sayed M, Fahmy R, Kasem A, Moubarak G, Zenhom A 2024. Cervical cancer screening by cytology and the burden of epithelial abnormalities in low resource settings: a tertiary-center 42-year study. BMC Women’s Health, 24(1).
  15. Foliaki S, Brewer N, Pearce N, Snijders PJF, Meijer CJLM, Waqatakirewa L, Clifford GM, Franceschi S 2014. Prevalence of HPV infection and other risk factors in a Fijian population. Infectious Agents and Cancer, 9(1), 1–8.
  16. Ghebre RG, Grover S, Xu MJ, Chuang LT, Simonds H 2017. Cervical cancer control in HIV-infected women: Past, present and future. In Gynecologic Oncology Reports (Vol. 21, pp. 101–108). Gynecol Oncol Rep.
  17. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet, 370(9581), 59–67.
  18. Hutchcraft ML, Miller RW 2022. Bleeding from Gynecologic Malignancies. In Obstetrics and Gynecology Clinics of North America (Vol. 49, Issue 3, pp. 607–622).
  19. Ibrahim Khalil A, Mpunga T, Wei F, Baussano I, de Martel C, Bray F, Stelzle D, Dryden-Peterson S, Jaquet A, Horner MJ, Awolude OA, Trejo MJ, Mudini W, Soliman AS, Sengayi-Muchengeti, M, Coghill AE, van Aardt, MC, De Vuyst H, Hawes SE, Clifford GM 2022. Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. International Journal of Cancer, 150(5), 761–772.
  20. Jug Rachel, Bean SM 2020. Cervix Cytology Bethesda System. Pathology Outlines - Bethesda system.PathologyOutlines.https://www.pathologyoutlines.com/topic/cervixcytologybethesda.html
  21. Kunatoga A, Mohammadnezhad M 2021. Health services related factors affecting the pap smear services in Fiji: a qualitative study. BMC Health Services Research, 21(1), 1–10.
  22. McLeod M, Harris R, Purdie G, Cormack D, Robson B, Sykes P, Crengle S, Iupati D, Walker N 2010. Improving survival disparities in cervical cancer between maori and non-Māori women in New Zealand: A national retrospective cohort study. Australian and New Zealand Journal of Public Health, 34(2), 193–199.
  23. Moodley JR, Constant D, Hoffman M, Salimo A, Allan B, Rybicki E, Hitzeroth I, Williamson AL 2009. Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: A cross-sectional study. BMC Cancer, 9, 275.
  24. Muthuramalingam MR, Muraleedharan VR 2023. Patterns in the prevalence and wealth-based inequality of cervical cancer screening in India. BMC Women’s Health, 23(1).
  25. Nowakowski A, Cybulski M, Buda I, Janosz I, Olszak-Wxąsik K, Bodzek P, Śliwczyński A, Teter Z, Olejek A, Baranowski W 2016. Cervical Cancer Histology, Staging and Survival before and after Implementation of Organised Cervical Screening Programme in Poland. Plos One, 11(5).
  26. Orbegoso C, Murali K,  Banerjee S 2018. The current status of immunotherapy for cervical cancer. In Reports of Practical Oncology and Radiotherapy (Vol. 23, Issue 6, pp. 580–588).
  27. Olorunfemi G, Ndlovu N, Masukume G, Chikandiwa A, Pisa PT, Singh E 2018. Temporal trends in the epidemiology of cervical cancer in South Africa (1994–2012). International Journal of Cancer, 143(9), 2238–2249.
  28. Pan X, Yang W, Wen Z, Li F, Tong L, Tang W 2020. Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis. Journal of Gynecologic Oncology, 31(6), 1–12.
  29. Pangarkar MA 2022. The Bethesda System for reporting cervical cytology. CytoJournal, 19.
  30. Pereira D, Garey SL 2020. Cancer, Cervical. In Encyclopedia of Behavioral Medicine (pp. 350–351).
  31. Quinn BA, Deng X, Colton A, Bandyopadhyay D, Carter JS, Fields EC 2019. Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival. Brachytherapy, 18(1), 29–37.
  32. Roy PS, Saikia BJ 2016. Cancer and cure: A critical analysis. In Indian Journal of Cancer (Vol. 53, Issue 3, pp. 441–442).
  33. Siegel RL, Miller KD, Fuchs HE,  Jemal A 2022. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33.
  34. StatBite: Prevalence of HPV in a cohort of U.S. men. 2009. Journal of the National Cancer Institute, 101(4), 223.
  35. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A,  Bray F 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
  36. Tay SK, Ngan HYS, Chu TY, Cheung ANY, Hseon Tay E 2008. Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong, Singapore and Taiwan. Vaccine, 26(SUPPL. 12).
  37. Townsend JS, Stormo AR, Roland KB, Buenconsejo-Lum L, White S, Saraiya M 2014. Current Cervical Cancer Screening Knowledge, Awareness, and Practices Among U.S. Affiliated Pacific Island Providers: Opportunities and Challenges. The Oncologist, 19(4), 383–393.
  38. Yin W, Wang J, Jiang L, James Kang Y 2021. Cancer and stem cells. In Experimental Biology and Medicine (Vol. 246, Issue 16, pp. 1791–1801).
  39. Zhang S, Xu H, Zhang L,  Qiao Y 2020. Cervical cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research, 32(6), 720–728.
  40. Zur Hausen H 2009. Papillomaviruses in the causation of human cancers - a brief historical account. In Virology (Vol. 384, Issue 2, pp. 260–265).

Cervical cancer is the fourth most common cancer in women globally, with 660,000 new cases reported in 2022 and 350,000 deaths. This study examined cervical cancer prevalence at Fiji's Colonial War Memorial Hospital (CWMH) from June 2016 to December 2023. The overall prevalence was 0.35%, with notable fluctuations: a significant rise from 2016 to 2017, stability until 2019, a COVID-19-related drop in 2020, and a gradual increase by 2023. Of the 352 diagnosed women, 74.15% were Fijian, 21.88% were of Indian ethnicity, and 2.27% were from other groups. Fijian women exhibited higher mortality. The majority (52.55%) of cases occurred in women aged 31-50, peaking at 41-45. Pap smear results showed 87.39% were negative, 11.01% were "Other," and 1.60% indicated epithelial cell abnormalities. The study highlights the persistent need for enhanced cervical cancer screening and prevention in Fiji.

Keywords : Cervical Cancer, Prevalence, Bethesda System, Cervical Intraepithelial Neoplasia.

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe